JORGE GABRIEL DOS SANTOS BATISTA

JORGE GABRIEL DOS SANTOS BATISTA

Página do item completo

Resultados de Busca

Agora exibindo 1 - 5 de 5

The role of probiotics in maintaining immune homeostasis
2022 - THIPE, VELAPHI C.; MENTOR, SHIREEN; LIMA, CAROLINE S.A.; FREITAS, LUCAS F.; FONSECA, ANA C.M.; NOGUEIRA, KAMILA M.; RODRIGUES, ADRIANA S.; BATISTA, JORGE G.S.; FERREIRA, ARYEL H.; LUGAO, ADEMAR B.
The immune system is a complex architecture of a collective and coordinated network regulated by various pathways to thermodynamically maintain immune homeostasis. The gut microbiota plays a pivotal role that offers significant stimuli (i.e., gut-brain, gut-lung, and gut-liver axis) for both innate and adaptive immunity, mediating immune and metabolic homeostasis. An intricate correlation between changes in the gut microbiota (dysbiosis) and common diseases/disorders have been attributed to the invasion of pathogens, constant use of antibiotics, and hypercytokinemia—a hallmark of immune homeostasis imbalance. These factors contribute to the severity of inflammatory diseases such as cardiovascular diseases, neurological disorders, and of late the coronavirus disease, Covid-19. Probiotics (Lactobacillus spp. and Bifidobacterium spp.) have been considered as alternative and/or adjuvant therapeutic in restoring the balance of gut microbiota for maintaining immune homeostasis and integrity. The probiotics catalyze dietary fibers and proteins to generate short-chain fatty acids and tryptophan to promote antiinflammatory cytokines, reduce epithelium permeability, reinforcing immunity in the gut mucosa, and regulating the systemic immune response. Herein, we review our overarching understanding of current applications of probiotics in amelioration of gut microbiome, and the improvement of gut barrier function and maintaining immune homeostasis. We also highlight clinical trials on probiotics with reported results for the treatment of inflammatory diseases. Additionally, the looming global Covid-19 pandemic makes it prudent to highlight the role of probiotics in both the innate and adaptive human immune responses, especially amid the Covid-19 vaccination paradigm.
Cu and Cu-based nanomaterials as nanofungicides
2022 - THIPE, VELAPHI C.; FREITAS, LUCAS F.; LIMA, CAROLINE S.A. de; NOGUEIRA, KAMILA M.; BATISTA, JORGE G.S.; FERREIRA, ARYEL H.; LUGAO, ADEMAR B.
Green nanotechnology through the production of copper and copper oxide nanoparticles (CuNPs and CuONPs, respectively) as nanofungicides brings forth the opportunity attributed to their antimicrobial properties in addition to Cu being an essential metal micronutrient that functions as a cofactor for many enzymatic activities in plants. Herein, we explore the use of CuNPs and CuONPs as nanofungicides against toxigenic fungi and their mechanism of action. We also highlight the green nanoagriculture and the ecotoxicology and safety of CuNPs and CuONPs as nanofungicides to significantly aid as agricultural breakthroughs because such approaches will provide realistic sustainable nano Cu-enabled products deemed safe for agricultural practices.
Silver nanoparticles applications and ecotoxicology for controlling mycotoxins
2021 - THIPE, VELAPHI C.; LIMA, CAROLINE S.A.; NOGUEIRA, KAMILA M.; BATISTA, JORGE G.S.; FERREIRA, ARYEL H.; KATTI, KATTESH V.; LUGAO, ADEMAR B.
The state of the art of theranostic nanomaterials for lung, breast, and prostate cancers
2021 - FREITAS, LUCAS F.; FERREIRA, ARYEL H.; THIPE, VELAPHI C.; VARCA, GUSTAVO H.C.; LIMA, CAROLINE S.A.; BATISTA, JORGE G.S.; RIELLO, FABIANE N.; NOGUEIRA, KAMILA; CRUZ, CASSIA P.C.; MENDES, GIOVANNA O.A.; RODRIGUES, ADRIANA S.; SOUSA, THAYNA S.; ALVES, VICTORIA M.; LUGAO, ADEMAR B.
The synthesis and engineering of nanomaterials offer more robust systems for the treatment of cancer, with technologies that combine therapy with imaging diagnostic tools in the so‐called nanotheranostics. Among the most studied systems, there are quantum dots, liposomes, polymeric nanoparticles, inorganic nanoparticles, magnetic nanoparticles, dendrimers, and gold nanoparticles. Most of the advantages of nanomaterials over the classic anticancer therapies come from their optimal size, which prevents the elimination by the kidneys and enhances their permeation in the tumor due to the abnormal blood vessels present in cancer tissues. Furthermore, the drug delivery and the contrast efficiency for imaging are enhanced, especially due to the increased surface area and the selective accumulation in the desired tissues. This property leads to the reduced drug dose necessary to exert the desired effect and for a longer action within the tumor. Finally, they are made so that there is no degradation into toxic byproducts and have a lower immune response triggering. In this article, we intend to review and discuss the state‐of‐the‐art regarding the use of nanomaterials as therapeutic and diagnostic tools for lung, breast, and prostate cancer, as they are among the most prevalent worldwide.
State of the art and current advances on protein cross-linking by irradiation: protein based nanocarriers and bioactive nanoparticles
2017 - VARCA, G.H.C.; MOHAMED, L.B.; FAZOLIN, G.N.; BATISTA, J.G.D.S.; QUEIROZ, R.G.; LUGAO, A.B.; NAVARRO MARQUES, F.A.; FERREIRA, A.H.
The highlighted role of protein and peptide based delivery systems relies upon the possibility to develop biocompatible drug carriers featuring site specific delivery, biological affinity among unique advantages. Recently, a technique for protein nanostructuring by the use of radiation has been recently reported by our group. Advantages of the use of radiation over conventional methods are related to the possibility to achieve protein cross-linking and sterilization in a single step, as well as the capacity to allow the design of nanocarriers without the need of monomers or toxic cross-linkers. This work reports the use of high energy irradiation towards the design of size-controlled protein-based nanocarriers and bioactive nanoparticles, using bovine serum albumin (BSA) and papain as model protein and protease, respectively, including the state of the art and current advances of the technology. The technique implies on protein desolvation/solvation techniques followed by cross-linking by EB radiation or -irradiation alone, although nanoparticles were also achieved in absence of the cosolvents. Size-controlled BSA nanocarriers were manufactured up to 80 nm and papain bioactive nanoparticles up to 12 nm, as determined by dynamic light scattering. Nanocarrier morphology was evaluated by and negative staining transmission electron microscopy. Protein cross-linking and changes in aromatic the amino acids were evaluated by fluorescence measurements. Biocompatibility experimentswere also performed by means of cytotoxicity and cytokines production. The potential of the systems for the delivery of radiopharmaceuticals or chemotherapeutic agents were also assayed, using technetium or Paclitaxel respectively. In conclusion, the technique allowed the production of biocompatible and bioactive protein nanoparticles suitable for the administration of radiopharmaceuticals and chemotherapeutic agents.